711569

antibody from Invitrogen Antibodies

Targeting: NPPA ANP, PND

Western blot (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

711569

Provider

Invitrogen Antibodies

Product name

ANP Recombinant Polyclonal Antibody (17 HCLC)

Antibody type

Polyclonal

Antigen

Synthetic peptide

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Antibody clone number

17 HCLC

Vial size

100 µg

Concentration

0.5 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Cardiac Protective Effect of Kirenol against Doxorubicin-Induced Cardiac Hypertrophy in H9c2 Cells through Nrf2 Signaling via PI3K/AKT Pathways.

Alzahrani AM, Rajendran P, Veeraraghavan VP, Hanieh H
International journal of molecular sciences 2021 Mar 23;22(6)

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis was performed on Tissue extracts (30 µg lysate) of Mouse heart (Lane 1), Rat heart (Lane 2), Mouse Brain (Lane 3) and Rat brain (Lane 4). The blots were probed with Anti-NPPA (ANP) Recombinant Rabbit Polyclonal Antibody (Product # 711569, 1-2 µg/mL) and detected by chemiluminescence using Goat anti-Rabbit IgG (H+L) Superclonal Secondary Antibody, HRP conjugate (Product # A27036, 0.4 µg/mL, 1:2500 dilution). A 17 kDa band corresponding to NPPA (ANP) was observed only in Heart tissue extracts tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12% Bis-Tris gel (Product # NP0321BOX), XCell SureLock Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5% skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western blotting Substrate (Product # 32106).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 2 Effects of KRL on DOX-induced hypertrophy. H9c2 cells were treated for 24 h with 15 uM of KRL, 2 h before DOX (0.25 umol) treatment. ( A ) Representative Western blots showing changes in the protein levels of ANP and BNP. ( B ) KRL is illustrated to downregulate MMP9 and MMP2. Western blot analysis was performed to determine the total protein MMP9 and MMp2 levels in the total extract by including beta-actin as an internal loading control. ( C ) H9c2 cells were treated for 24 h with 10 and 15 uM of KRL, 2 h before the DOX (0.25 umol) treatment. The cells then underwent actin filament staining to observe the changes in the surface area of the cardiomyocytes. Scale bar indicated 100u m at 20x magnification. Data are represented as the mean +- SD of triplicate values ( n = 3) and * p < 0.05 represents significant variations compared with the control. # p < 0.05 represents significant variations as compared to DOX alone and KRL with DOX treatment groups.